Research Topics
| DUANE MITCHELLSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteersChris A Learn
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 12:7306-15. 2006....- Selective modification of antigen-specific T cells by RNA electroporationDuane A Mitchell
Division of Neurosurgery, Department of Surgery, Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
Hum Gene Ther 19:511-21. 2008.... - Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastomaDuane A Mitchell
Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA
Neuro Oncol 10:10-8. 2008.... - Immunotherapy of malignant brain tumorsDuane A Mitchell
Division of Neurosurgery, Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke, NC 27710, USA
Immunol Rev 222:70-100. 2008.... - Toward effective immunotherapy for the treatment of malignant brain tumorsDuane A Mitchell
Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
Neurotherapeutics 6:527-38. 2009.... - Adoptive immunotherapy for malignant gliomaDuane A Mitchell
Department of Pathology and Department of Surgery, Duke University Medical Center, Box 3807, Durham, NC 27710, USA
Cancer J 9:157-66. 2003.... - Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cellsPeter E Fecci
Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 12:4294-305. 2006..This leads to safe enhancement of tumor immunity in a murine glioma model that recapitulates the tumor-induced changes to the CD4 and T(reg) compartments seen in patients with malignant glioma... - EGFRvIII-targeted vaccination therapy of malignant gliomaBryan D Choi
Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Brain Pathol 19:713-23. 2009..Additionally, the corresponding therapeutic outcomes observed in these studies lend credence to the potential role of peptide-based vaccination strategies among emerging antitumor immunotherapies in patients with malignant glioma... - Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccinesRobert J Schmittling
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Immunol Methods 339:74-81. 2008..Using this assay, we found that significant levels of antibody for tumor-specific antigen EGFRvIII (>4 microg/mL) and KLH could be induced after vaccination with PEPvIII-KLH... - Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant gliomaJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Semin Immunol 20:267-75. 2008..The recurrence of EGFRvIII-negative tumors in our patients, however, highlights the need for targeting a broader repertoire of tumor-specific antigens... - Proteomic and immunologic analyses of brain tumor exosomesMichael W Graner
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
FASEB J 23:1541-57. 2009..They can escape the blood-brain barrier, with potential systemic and distal signaling and immune consequences... - The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumorsPeter E Fecci
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 64:161-76. 2003..The future success of clinical trials will depend on the optimization and standardizing of procedures for DC generation, loading, and administration... - Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJohn H Sampson
Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 28:4722-9. 2010..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms... - Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant gliomaPeter E Fecci
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 66:3294-302. 2006..These findings dramatically alter our understanding of depressed cellular immune function in patients with malignant glioma and advance a role for T(regs) in facilitating tumor immune evasion in the central nervous system... - EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cellsHidenobu Ochiai
Department of Surgery Neurosurgery, Duke University Medical Center, Box 3050, Durham, NC, 27710, USA
Cancer Immunol Immunother 57:115-21. 2008..However, delayed and often dramatic antitumor responses seen in human studies with targeted toxins led us to hypothesize that immunologic responses may be a secondary mechanism that enhances the therapeutic efficacy of these novel drugs... - Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell functionPeter E Fecci
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 13:2158-67. 2007..Our murine glioma model recapitulates these findings. Here, we investigate the effects of systemic CTLA-4 blockade in this model... - Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunityChris A Learn
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States
J Neuroimmunol 182:63-72. 2007..Our findings support our hypothesis that glioma phenotype in vitro may be quite different in vivo and significantly altered by in situ growth factors and other invading cell populations... - An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Mol Cancer Ther 8:2773-9. 2009..7 months (C.I.(95), 14.5-25.6). Overall median survival from time of histologic diagnosis was 22.8 months (C.I.(95), 17.5-29). This study establishes the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immunotherapy... - Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case studyAmy B Heimberger
Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Neuro Oncol 10:98-103. 2008..In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery...
Research Grants
- Reversal of CMV-specific immune deficits in patients with glioblastomaDuane Anthony Mitchell; Fiscal Year: 2010..Improved therapy for cancer has significant potential to improve public health and quality of life for patients affected by malignant disease. ..
- Adoptive Immunotherapy for GBM During Hematopoietic Recovery from TemozolomideDuane Anthony Mitchell; Fiscal Year: 2010..Improved therapy for cancer has significant potential to improve public health and quality of life for patients affected by malignant disease. ..